In biopsy-confirmed F2 MASH with a lean BMI, what phenotype features (e.g., visceral adiposity, worsening glycemia/prediabetes, atherogenic dyslipidemia) most strongly push you toward a GLP-1 receptor agonist first versus a thyroid hormone receptor-beta agonist first versus upfront combination therapy?